Basic research for development of CTL-inducible vaccine against West Nile virus using recombinant E protein

利用重组E蛋白开发抗西尼罗病毒CTL诱导疫苗的基础研究

• 批准号: 19590604
• 负责人: MASAKI Hideyuki
• 金额: $ 2.91万
• 依托单位: Kinki University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2007
• 资助国家: 日本
• 起止时间: 2007 至 2010
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-19590604/
• 关键词: ウエストナイルウイルス; E蛋白質; 成分ワクチン; 組換えワクチン; CTL; cross-presentation; 中和抗体; 感染防御; 感染防護

West Nile virus (WNV) is the human-infectious virus, which sometimes causes lethal encephalitis/meningitis, and the vaccine for human use has not been developed yet. Based on the findings concerning its relative viruses, it is anticipated that the envelope (E) protein should induce protective immunity. In the present study, we have established several recombinant WNV E protein expression systems and the CTL target cells in order to develop the recombinant component vaccine against WNV infection, which induces not only neutralizing antibody but also CTL, using recombinant WNV E protein combined with cross-presentation inducing adjuvant.

西尼罗河病毒（WNV）是人类感染性病毒，有时会引起致命性脑炎/脑膜炎，尚未开发用于人类使用的疫苗。根据有关其相对病毒的发现，预计包膜（E）蛋白应诱导保护性免疫。在本研究中，我们已经建立了几种重组WNV E蛋白表达系统和CTL靶细胞，以开发针对WNV感染的重组成分疫苗，这些疫苗针对WNV感染，这不仅诱导了中和CTL，而且还使用重组WNV E蛋白与交叉特征诱导的辅助辅助抗体相结合。